85 related articles for article (PubMed ID: 19047306)
1. Quo vadis with targeted drugs in the 21st century?
Bergh J
J Clin Oncol; 2009 Jan; 27(1):2-5. PubMed ID: 19047306
[No Abstract] [Full Text] [Related]
2. [Sorafenib].
Hansen A; Eschenhagen T
Dtsch Med Wochenschr; 2010 Sep; 135(37):1819-22. PubMed ID: 20730706
[No Abstract] [Full Text] [Related]
3. Population differences in the use of EGFR-targeted agents.
Saijo N
Clin Adv Hematol Oncol; 2008 Oct; 6(10):730-2. PubMed ID: 18997662
[No Abstract] [Full Text] [Related]
4. Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Moncrieff M; Shannon K; Hong A; Hersey P; Thompson J
Melanoma Res; 2008 Apr; 18(2):161-2. PubMed ID: 18337654
[TBL] [Abstract][Full Text] [Related]
5. [Targeted HCC therapies: the door has been opened!].
Rosmorduc O; Fartoux L
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969
[No Abstract] [Full Text] [Related]
6. Foreword.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):244. PubMed ID: 20082841
[No Abstract] [Full Text] [Related]
7. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
8. Introduction: targeting different pathways to prevent tumor cell development.
Kantarjian HM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S1-5. PubMed ID: 19393830
[No Abstract] [Full Text] [Related]
9. Therapeutic strategies for triple-negative breast cancer.
Tan AR; Swain SM
Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
11. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
12. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
13. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
14. Neratinib Graduates to I-SPY 3.
Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
[No Abstract] [Full Text] [Related]
15. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib (Ibrance) for metastatic breast cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
[No Abstract] [Full Text] [Related]
17. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
18. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]